clopidogrel

Originally published Oct. 31.
NEW YORK (GenomeWeb) – Spartan Bioscience is gearing up to commercialize its CYP2C19 test in Canada in the point-of-care setting, a previously untapped market for the company.

Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling?

A study led by researchers from Brigham and Women's Hospital on the effect of CYP2C19 testing on physicians' prescribing patterns has found that when doctors received patient test results for genetic markers associated with clopidogrel response through a pharmacy-benefit manager-

This article has been updated to note that PDI is moving away from the contract sales business with drug companies. Originally published Oct. 22.

Having published research last year identifying a novel haplotype that may alter the interpretation of CYP2C19 genotyping, clinical researchers from the Icahn School of Medicine at Mount Sinai in New York have now published a paper describing an allele-specific PCR assay to detec

Having garnered 510(k) regulatory clearance in August for its rapid-analysis CYP2C19 genetic test, Spartan Bioscience will continue to work with the US Food and Drug Administration to try to gain the agency's okay for marketing the test in the point-of-care setting.

Canadian molecular diagnostics developer Spartan Bioscience said this week that the US Food and Drug Administration has granted 510(k) clearance to the Spartan RX CYP2C19 assay.

Originally published Aug. 19. The University of Florida's experience implementing a pharmacogenetic testing program for clopidogrel is becoming a blueprint for bringing personalized medicine strategies to the community healthcare setting.

Originally published March 12.